IDP-023 is a highly potent natural killer cell platform under evaluation for patients with multiple myeloma and non-Hodgkin lymphoma.
Indapta Therapeutics has received FDA Fast Track Designation for its natural killer (NK) cell therapy IDP-023 for patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL).1 The company’s universal, allogeneic NK cell therapy platform is comprised of a potent subset of naturally occurring NK cells called G minus NK (g-NK) cells.
In clinical research, these cells have demonstrated significantly superior killing capacity than conventional NK cells without requiring genetic engineering of the cells. For manufacturing of IDP-023, Indapta extracts g-NK cells from healthy donors with greater numbers of g-NK cells and low donor-to-donor variability.2
“This designation highlights the promise of Indapta’s highly potent NK cell platform and will further accelerate clinical development of our lead drug candidate, IDP-023, for two of the largest unmet needs in B-cell driven blood cancers, NHL and multiple myeloma,” said Mark Frohlich, MD, chief executive officer of Indapta Therapeutics, in a press release.1
Preclinical research has shown that IDP-023 produces more potent and durable antitumor activity than cancer-targeting monoclonal antibodies (mAbs) compared to conventional NK cells.
“(mAbs) are a central component of therapy for hematologic malignancies. Widely used mAb agents in (MM) include daratumumab and elotuzumab. However, not all patients respond to these agents, and resistance is a significant clinical issue,” wrote the authors of a study published by Blood Advances. “A recently discovered subset of human natural killer (NK) cells lacking expression of FcεRIγ (g-NK cells) was found to have a multifold increase in antibody-dependent effector functions after CD16 crosslinking.”3
For the study, the researchers evaluated the ability of g-NK cells to improve the efficacy of mAbs against MM. An in vitro analysis suggested that g-NK cells combined with daratumumab or elotuzumab have significantly superior anti-myeloma cytotoxicity compared with conventional NK cells.
An evaluation of in vivo efficacy found combining daratumumab and g-NK cells produced a >99.9% tumor reduction compared with daratumumab combined with conventional NK cells. Further, the daratumumab plus g-NK cells combination completely eradicated the myeloma burden in five of seven mice.
“It is noteworthy that the combination of g-NK cells with daratumumab was able to completely eliminate tumor in a disseminated orthotopic xenograft MM.1S model of MM,” the study authors wrote. “We are currently focusing on larger-scale expansion and donor standardization to create a clinical-grade product for evaluation in human trials. In conclusion, we propose that this novel NK cell therapy could be administered in an off-the-shelf manner to supercharge mAb efficacy in MM and eventually other malignancies as well.”3
Indapta Therapeutics began treating the first patients with IDP-023 in January 2024 at NEXT Oncology in Virginia and The University of Texas MD Anderson Cancer Center in Houston.4 The first patient enrolled in the study was administered a single dose of IDP-023, with a second patient administered the first of three planned doses. Additional patient groups will receive three doses of the drug with or without IL-2.
References
1. Indapta Therapeutics receives U.S. FDA fast track designation for lead clinical drug candidate IDP-023 for non-Hodgkin’s lymphoma and myeloma. News release. Indapta Therapeutics. February 29, 2024. Accessed February 29, 2024. https://www.businesswire.com/news/home/20240229681905/en
2. Allogeneic natural killer cells IDP-023. National Cancer Institute. Accessed February 29, 2024. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/allogeneic-natural-killer-cells-idp-023
3. Austin B. Bigley, Shanae Spade, Nadia H. Agha, Sujit Biswas, Suni Tang, Muhammad H. Malik, Lu Dai, Shalaleh Masoumi, Bonell Patiño-Escobar, Martina Hale, Guy DiPierro, Ronald Martell, Byron Hann, Nina Shah, Arun P. Wiita, Xinli Liu; FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma. Blood Adv 2021; 5 (15): 3021–3031. doi: https://doi.org/10.1182/bloodadvances.2020002440
4. Indapta Therapeutics announces first patients treated with IDP-023 allogeneic natural killer (NK) cell therapy for cancer. News release. Indapta Therapeutics. January 11, 2024. Accessed February 29, 2024. https://www.businesswire.com/news/home/20240111941372/en/Indapta-Therapeutics-Announces-First-Patients-Treated-with-IDP-023-Allogeneic-Natural-Killer-NK-Cell-Therapy-for-Cancer
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.